🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 88 of 114

  1. Suzetrigine (SUZ)

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial

  2. Suzhou Sceneray® DBS System

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Opiate Addiction

    phase 3 other active

    1 trial

  3. Symbicort Turbuhaler

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  4. Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, BFF (PT009), BD ( PT008), SALBUTAMOL, Placebo MDI and empty TBH devices (only for training purposes)

    AstraZeneca AB

    Inadequately Controlled Asthma

    phase 3 small molecule active

    1 trial

  5. Synthetic Conjugated estrogens, B

    Teva Pharma GmbH

    Menopause

    phase 3 small molecule completed

    1 trial

  6. Systematic oral health education

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor of Head and/or Neck

    phase 3 other completed

    1 trial

  7. T89 Placebo; capsules contain brown coated dripping pills., Nitroglycerin Orifarm 0,5 mg tabletes lietošanai zem mēles

    Lacuna Pharma Pty Ltd

    Stable Angina Pectoris

    phase 3 small molecule active

    1 trial

  8. TACROLIMUS, ALPN-303 solution for injection in pre-filled syringe, TACROLIMUS, TACROLIMUS, ALPN-303 solution for injection, Test IMP without active substance, ALPN-303 Solution for Injection in Pre-filled Pen

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

  9. TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan

    AstraZeneca AB

    Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  10. TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, CISPLATIN, PEMETREXED

    AstraZeneca AB

    Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.

    phase 3 small molecule active

    1 trial

  11. TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation

    phase 3 small molecule active

    1 trial

  12. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  13. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  14. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo

    AstraZeneca AB

    Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.

    phase 3 small molecule active

    1 trial

  15. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet

    Janssen-Cilag International N.V.

    EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. TAK-003

    Takeda

    Dengue Fever

    phase 3 mab completed

    1 trial

  17. TAK-019

    Takeda

    Coronavirus Disease (COVID-19)

    phase 3 mab completed

    1 trial

  18. TAK-279

    Takeda

    Generalized Pustular Psoriasis

    phase 3 small molecule active

    1 trial

  19. TAK-279

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    3 trials

  20. TAK-330

    Takeda

    Coagulation Disorder

    phase 3 small molecule active

    1 trial

  21. TAK-438

    Takeda

    Non-erosive Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  22. TAK-438

    Takeda

    Gastric Ulcer

    phase 3 small molecule completed

    4 trials

  23. TAK-438

    Takeda

    Duodenal Ulcer

    phase 3 small molecule completed

    2 trials

  24. TAK-438

    Takeda

    Erosive Esophagitis

    phase 3 small molecule completed

    4 trials

  25. TAK-438

    Takeda

    Gastric Ulcers

    phase 3 small molecule completed

    4 trials

  26. TAK-438

    Takeda

    H. Pylori Infection

    phase 3 small molecule completed

    1 trial

  27. TAK-536

    Takeda

    Hypertension

    phase 3 small molecule completed

    1 trial

  28. TAK-536CCB

    Takeda

    Grade I or II Essential Hypertension

    phase 3 small molecule completed

    1 trial

  29. TAK-536TCH tablet

    Takeda

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  30. TAK-559

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  31. TAK-559 and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  32. TAK-559 and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  33. TAK-559 and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  34. TAK-583

    Takeda

    Neuralgia, Postherpetic

    phase 3 small molecule completed

    1 trial

  35. TAK-625

    Takeda

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    1 trial

  36. TAK-625

    Takeda

    Alagille Syndrome (ALGS)

    phase 3 small molecule completed

    1 trial

  37. TAK-667

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  38. TAK-672

    Takeda

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  39. TAK-743 300 mg

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  40. TAK-755

    Takeda

    Thrombotic Thrombocytopenic Purpura (TTP)

    phase 3 mab active

    3 trials

  41. TAK-771

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  42. TAK-771

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 small molecule completed

    2 trials

  43. TAK-788

    Takeda

    Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  44. TAK-816

    Takeda

    Healthy Volunteers

    phase 3 mab completed

    1 trial

  45. TAK-816+ DPT-TAKEDA

    Takeda

    Immunization

    phase 3 mab completed

    1 trial

  46. TAK-861

    Takeda

    Narcolepsy Type 1

    phase 3 small molecule active

    4 trials

  47. TAK-861

    Takeda

    Narcolepsy Type 1 (NT1)

    phase 3 small molecule active

    1 trial

  48. TAK-861, TAK-861 placebo (same excipients as TAK-861)

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.